Armata is meeting the global challenge of antibiotic resistance by developing high-impact, best-in-class phage therapeutics. Learn more about how Armata is leading the fight against antibiotic resistance See what scientists worldwide are saying about antibiotic resistance » Explore Our Company »| Armata Pharmaceuticals
Department: Quality Control Reports To: QC Analyst III/Team Lead Job Location: 100 % Onsite – Los Angeles, CA Position Summary The QC Analyst II performs analytical testing on raw materials, in-process samples, and final products to ensure compliance with established quality specifications. This role supports method execution, troubleshooting, and documentation under moderate supervision and contributes […] The post QC Analyst II appeared first on Armata Pharmaceuticals.| Armata Pharmaceuticals
Department: Quality Control Reports To: QC Analyst III/Team Lead Job Location: 100 % Onsite – Los Angeles, CA Position Summary The QC Analyst I supports laboratory operations by performing basic analytical testing and assisting with quality control activities under supervision. This entry-level position provides training and development in cGMP laboratory practices and routine QC assays […]| Armata Pharmaceuticals
Bani Tchekanova PhD, was appointed Head of Regulatory Strategy and Operations of Armata in July 2025. Prior to joining Armata, Bani Served as a Chief Principal Advisor at ClinReg Partners, LLC. Bani brings with her over 25 years of diverse and dynamic experience in global drug development and regulatory affairs. Her career spans a wide array […]| Armata Pharmaceuticals
Dr. Schlesinger has served as a member of Armata’s board of directors since February 2020. Dr. Schlesinger has served as a member of the Board of Directors of Innoviva, Inc. since 2018, and serves on its Compensation Committee and as chairperson of its Nominating/Corporate Governance Committee. Dr. Schlesinger is an Associate Professor of Clinical Investigation […]| Armata Pharmaceuticals
Mr. Patel has 15 years’ experience in pharmaceuticals, medical devices, and combination products. Leading Armata’s Quality Assurance department, Mr. Patel is responsible for ensuring compliance with cGMP and GLP standards in the manufacturing and testing of Armata’s investigational phage products, as well as ensuring GCP compliance in the conduct of human clinical trials. Prior to […]| Armata Pharmaceuticals
David House was appointed Senior Vice President, Finance and Principal Financial Officer on August 16, 2024. Previously, Mr. House served as Corporate Controller and Vice President of Accounting at ZO Skin Health, Inc., a multi-channel physician-dispensed skincare company, from October 2018 to May 2024. At ZO Skin Health, he led global accounting operations, managed financial […]| Armata Pharmaceuticals
The post Bacteria-eating viruses could provide a route to stability in cystic fibrosis: Phage therapy is broadening the treatment landscape for people with drug-resistant infections. appeared first on Armata Pharmaceuticals.| Armata Pharmaceuticals
The post Safety of Bacteriophage Therapy in Severe <em>Staphylococcus aureus</em> Infection. appeared first on Armata Pharmaceuticals.| Armata Pharmaceuticals
Peter leads Armata’s operations team with over 17 years of experience in biotech and pharmaceutical production with companies like Baxter Bioscience, GlaxoSmithKline, Pacira Pharmaceuticals and Kite Pharma. Most recently, he was the Director of Manufacturing at Armata Pharmaceuticals where he led the manufacturing team starting in 2022 and helped to build out greater manufacturing capabilities. Prior […] The post Peter Hubbard appeared first on Armata Pharmaceuticals.| Armata Pharmaceuticals
Dr. Kyme is devoted to Armata’s business and corporate development activities, a role that started at C3J Therapeutics in 2015. Previously, Dr. Kyme served as Director of Product Development at C3J Therapeutics from 2012, leading a team that set strategy and delivered key data essential for advancing a lead antimicrobial molecule through Phase 2 human […]| Armata Pharmaceuticals
Deborah L. Birx, M.D., was appointed Chief Executive Officer of Armata on July 10, 2023. Prior to joining Armata, Dr. Birx served as a member of Innoviva’s Board of Directors from March 2021 until July 2023. Dr. Birx is a world-renowned medical expert and leader who most recently served as the response coordinator of the […]| Armata Pharmaceuticals
